Psoriatic Arthritis

Tofacitinib improves enthesitis in patients with psoriatic arthritis regardless of severity or location at baseline, according to data published in Arthritis Research and Therapy.

Healio spoke with two clinicians from Johns Hopkins University about the psoriatic arthritis treatment landscape, specifically touching on JAK inhibitor and interleukin-6 agents.

Healio spoke with two clinicians from Johns Hopkins University about the psoriatic arthritis treatment landscape, specifically touching on JAK inhibitor and interleukin-6 agents.

SAN DIEGO — Izokibep, a novel interleukin-17A inhibitor and nanobody drug, demonstrates “high rates of response” in psoriatic arthritis through 46 weeks, according to a speaker at ACR Convergence 2023.

SAN DIEGO — In patients with psoriatic arthritis, those with female sex are less likely than those with male sex to achieve outcomes in randomized clinical trials for advanced therapies, according to data presented at ACR Convergence 2023.

SAN DIEGO — Apremilast is superior to placebo regarding joint response and disease control in patients with early oligoarticular psoriatic arthritis, according to data presented at ACR Convergence 2023.

In patients with psoriatic arthritis and an inadequate response to TNF inhibitors, guselkumab reduces levels of effector cytokines linked to arthritis and skin disease activity, according to data published in Arthritis Research & Therapy.

A new tool using readily available clinical variables to predict psoriatic arthritis risk in patients with psoriasis demonstrated reasonable accuracy and good model performance, according to data published in Arthritis & Rheumatology.

The FDA has approved Wezlana as a Stelara biosimilar for the treatment of plaque psoriasis, psoriatic arthritis and other inflammatory diseases, according to an FDA press release.

Bimekizumab remains effective after 52 weeks in patients with psoriatic arthritis, with no new safety concerns, according to data published in Annals of the Rheumatic Diseases.